Research Papers:
Laminarin promotes anti-cancer immunity by the maturation of dendritic cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2662 views | HTML 3364 views | ?
Abstract
Kyeongeun Song1,2,*, Li Xu1,*, Wei Zhang1, Yun Cai1, Bian Jang1,2,3,4, Junghwan Oh2,3,4 and Jun-O Jin1
1Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan University, Shanghai, 201508, China
2Marine-Integrated Bionics Research Center, Pukyong National University, Busan, 48513, Korea
3Department of Biomedical Engineering and Center for Marine-Integrated Biomedical Technology (BK21 Plus), Pukyong National University, Busan, 48513, Korea
4Interdisciplinary Program of Biomedical Mechanical and Electrical Engineering, Pukyong National University, Busan, 48513, Korea
*These authors have contributed equally to this work
Correspondence to:
Jun-O Jin, email: [email protected]
Keywords: laminarin, adjuvant, anti-cancer, dendritic cell maturation, cytotoxic lymphocyte activation
Received: December 28, 2016 Accepted: February 20, 2017 Published: March 14, 2017
ABSTRACT
This research evaluates the effects of laminarin on the maturation of dendritic cells and on the in vivo activation of anti-cancer immunity. In vivo treatment of C56BL/6 mice with laminarin increased the expression levels of co-stimulatory molecules and the production of pro-inflammatory cytokines in spleen dendritic cells. Laminarin enhanced ovalbumin antigen presentation in spleen dendritic cells and promoted the proliferation of OT-I and OT-II T cells. Laminarin also induced the maturation of dendritic cells in tumor-draining lymph nodes and protected interferon-γ and tumor necrosis factor-α and proliferation of OT-I and OT-II T cells in tumors. The combination treatment of laminarin and ovalbumin inhibited B16-ovallbumin melanoma tumor growth and its liver metastasis by antigen-specific immune activation, including cytotoxic T lymphocyte activation and interferon-γ production. Thus, these data demonstrated the potential of laminarin as a new and useful immune stimulatory molecule for use in cancer immunotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16170